ABBVIE INC. By Sabela Ojea
AbbVie said that the U.S. Food and Drug Administration approved Epkinly as the first and only T-cell bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
The pharmaceutical company on Wednesday said that the Epkinly treatment has shown deep and durable responses for many patients.
Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, but AbbVie will be responsible for further global commercialization.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
06-26-24 1950ET
